What smart money is saying about IQVIA Holdings Inc
6 funds in our archive have pitched IQVIA Holdings Inc, most recently Artisan Partners Global Value Fund in September 2026.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
Get an email when a fund buys, sells or pitches it
Fund signal · last 12 months
25 lettersFunds are split between buying and selling
Moves described in fund letters in our archive. A sentence published word for word by several funds of one house in the same quarter counts once.
Position history
Between Q4 2024 and Q3 2026, 30 fund letters reported a position in IQVIA Holdings Inc, with 3 buys (opened or added) and 4 sells (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 17 | 2 | 3 | 2 |
| Q2 2026 | 2 | 0 | 0 | 0 |
| Q1 2026 | 6 | 1 | 1 | 2 |
| Q2 2025 | 3 | 0 | 0 | 2 |
| Q4 2024 | 2 | 0 | 0 | 0 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 30 positions · 10 moves
- September 2026
“TOP CONTRIBUTOR | DETRACTOR Top contributor IQVIA was a contributor during the quarter.”
IQVIA Holdings Inc - September 2026
Listed in Oakmark Equity and Income Fund’s reported holdings.
IQVIA Holdings Inc - HoldsOakmark Global FundSeptember 2026
“Top contributor IQVIA was a contributor during the quarter.”
IQVIA Holdings Inc - September 2026
“Top contributors to performance included Illumina, Inc., IQVIA Holdings Inc., and SharkNinja, Inc. Illumina benefited from continued uptake for its DNA sequencing technology as well as a positive outlook for diagnostics from Grail, a company it was compelled to spin out but where they retain a significant equity stake. IQVIA reported good revenue growth, but more importantly a solid backlog and outlook as its pharmaceutical industry clients ramp up their research and development.”
IQVIA Holdings Inc - September 2026
“Portfolio Commentary The Large Cap Equity composite was up 1.19% in the quarter, net of fees, compared to a return of 2.30% for the S&P 500. Top contributors to performance included Illumina, Inc., IQVIA Holdings Inc., and SharkNinja, Inc. Illumina benefited from continued uptake for its DNA sequencing technology as well as a positive outlook for diagnostics from Grail, a company it was compelled to spin out but where they retain a significant equity stake. IQVIA reported good revenue growth, but more importantly a solid backlog and outlook as its pharmaceutical industry clients ramp up their research and development.”
IQVIA Holdings Inc - September 2026
“IQVIA shares were up 39% as industry demand trends improved in drug development and the notion that the company was AI roadkill lost a bit of steam. Biotech funding, a leading indicator of development spending for this customer cohort, rose 60% year over year in Q3. Drug development activity at large pharma is also improving. Together, these lifted book-to-bill ratios across the contract research organization (CRO) space, pointing to accelerating revenue growth. The AI bear case for companies like IQVIA seems to be losing momentum. Pharma sponsors have indicated the primary uses of AI will be in drug discovery rather than in clinical trials, implying the CRO model is durable. At the same time, IQVIA expects AI to be a tailwind and is using its data assets to roll out AI tools that management believes are already lifting win rates. We expect revenue growth to return to IQVIA’s mid-to-high single-digit target. Modest operating leverage and ongoing buybacks should drive double-digit EPS growth in the medium term. The shares have responded to the improving industry fundamentals and now trade at 20X forward earnings. We view this as a fair price and trimmed our position during the quarter.”
IQVIA Holdings Inc - September 2026
“We sold IQVIA Holdings during the quarter. The company is the largest healthcare contract research organization (CRO) in the world. CROs are hired by sponsors ranging from large pharma to small biotech and medical device companies to support research, development and ultimately the commercialization of drugs, vaccines and devices. We purchased IQVIA in the summer of 2025 at a time when large pharma clients were re-prioritizing and pausing work in response to persistent inflation, higher rates, and policy uncertainty. At the same time, small biotech clients were experiencing a more difficult funding environment due to similar dynamics. Given our long-term time horizon, admiration for the business, and confidence in IQVIA’s management, we looked through these short-term headwinds and purchased the business at below 50 cents on the dollar of our estimate of intrinsic value. Over our ownership period, our value per share grew, supported by healthy earnings, billions of dollars of free cash flow, and management’s intelligent deployment of that cash. Fast forward to today and IQVIA’s customers are now spending at a more normal cadence, and revenue growth has accelerated. As a result, the company’s share price has risen and is now trading closer to our estimate of value per share. Given how attractive other opportunities are within our portfolio, we have exited IQVIA to fund more deeply discounted businesses.”
IQVIA Holdings Inc - September 2026
“IQVIA shares were up 39% as industry demand trends improved in drug development and the notion that the company was AI roadkill lost a bit of steam. Biotech funding, a leading indicator of development spending for this customer cohort, rose 60% year over year in Q3. Drug development activity at large pharma is also improving. Together, these lifted book-to- bill ratios across the contract research organization (CRO) space, pointing to accelerating revenue growth. The AI bear case for companies like IQVIA seems to be losing momentum. Pharma sponsors have indicated the primary uses of AI will be in drug discovery rather than in clinical trials, implying the CRO model is durable. At the same time, IQVIA expects AI to be a tailwind and is using its data assets to roll out AI tools that management believes are already lifting win rates. We expect revenue growth to return to IQVIA’s mid-to-high single-digit target. Modest operating leverage and ongoing buybacks should drive double-digit EPS growth in the medium term. The shares have responded to the improving industry fundamentals and now trade at 20X forward earnings. We view this as a fair price and trimmed our position during the quarter.”
IQVIA Holdings Inc - September 2026
“IQVIA shares were up 39% as industry demand trends improved in drug development and the notion that the company was AI roadkill lost a bit of steam. Biotech funding, a leading indicator of development spending for this customer cohort, rose 60% year over year in Q3. Drug development activity at large pharma is also improving. Together, these lifted book-to- bill ratios across the contract research organization (CRO) space, pointing to accelerating revenue growth. The AI bear case for companies like IQVIA seems to be losing momentum. Pharma sponsors have indicated the primary uses of AI will be in drug discovery rather than in clinical trials, implying the CRO model is durable. At the same time, IQVIA expects AI to be a tailwind and is using its data assets to roll out AI tools that management believes are already lifting win rates. We expect revenue growth to return to IQVIA’s mid-to-high single-digit target. Modest operating leverage and ongoing buybacks should drive double-digit EPS growth in the medium term. The shares have responded to the improving industry fundamentals and now trade at 20X forward earnings. We view this as a fair price and trimmed our position during the quarter.”
IQVIA Holdings Inc - September 2026
“We view this as a fair price and trimmed our position during the quarter.”
IQVIA Holdings Inc - TrimmedBroyhill Equity CompositeSeptember 2026
“IQVIA was our largest contributor, adding about 320 basis points, most of it in July. Second-quarter results beat expectations on revenue, earnings and bookings, and management raised its full-year earnings guidance. The shares jumped 12% on the report to a new 52-week high. We trimmed the position in August as part of our portfolio construction discipline.”
IQVIA Holdings Inc - AddedWCM Global Growth LimitedSeptember 2026
“Within the Health Care sleeve, AstraZeneca and Medline were exited in favour of CVS Health and IQVIA Holdings.”
IQVIA Holdings Inc - September 2026
“IQVIA was a contributor during the quarter.”
IQVIA Holdings Inc - September 2026
“Top contributors: • IQVIA was a contributor during the quarter.”
IQVIA Holdings Inc - September 2026
“Top contributors: • IQVIA was a contributor during the quarter.”
IQVIA Holdings Inc - September 2026
“• IQVIA was a contributor during the quarter.”
IQVIA Holdings Inc - July 2026
“Our holdings in Dexcom and IQVIA were the strongest examples of this, after reporting solid earnings and allaying some of the concerns which we felt were unjustified.”
IQVIA Holdings Inc - June 2026
“IQVIA, one of our largest holdings, is apparently in AI’s cross hairs.”
IQVIA Holdings Inc - June 2026
“The roadkill basket is a hyper-simplified collection of companies that apparently are going to be disrupted by AI. We have seen a number of such baskets circulating among traders. Below is an example of some of the most common names we have seen circulating on these lists: Accenture PLC Adobe Inc Automatic Data Processing Inc Booking Holdings Inc Cognizant Technology Solutions Corp FactSet Research Systems Inc Gartner Inc IQVIA Holdings Inc Paychex Inc The Charles Schwab Corp Given what we know about these names, we suspect that the list was put together by a freshly minted, sleep-deprived MBA feeding prompts into ChatGPT. In the trading world, nuance is out the window. It’s about selling stories. It’s about the inability to disprove the negative. IQVIA, one of our largest holdings, is apparently in AI’s cross hairs.”
IQVIA Holdings Inc - March 2026
“Portfolio Commentary In the first quarter of 2026 the Large Cap Equity composite eked out a gain of 0.57% net of fees compared to a loss of 4.33% for the S&P 500. What became clear is that companies with strong backlogs of customer business were rewarded and those with more economically sensitive customers underperformed. The best contributors were led by Vertiv Holdings Co., Advanced Energy Industries, Inc., and Curtiss- Wright Corporation. All three saw customer order growth adding to already strong backlogs in their respective fields of computing infrastructure, and aerospace/nuclear power. We continue to monitor their business closely for cracks in the foundation but remain confident that they are essential to customers and the prospects for growth are solid. Detractors were led by Estee Lauder Companies Inc. While there remains a strong case for accelerating profit growth based on better execution and a more efficient operation, the combination of the war and its impact on consumer spending, along with a proposed merger with a competitor caused the stock price to reset. We will evaluate whether our 3-5 year thesis is affected by these events. Also detracting was IQVIA Holdings Inc.”
IQVIA Holdings Inc - March 2026
“• IQVIA Holdings was a detractor during the quar- ter.”
IQVIA Holdings Inc - March 2026
“Portfolio Commentary In the first quarter of 2026 the Select Equity composite eked out a gain of 1.17% net of fees compared to a loss of 4.33% for the S&P 500. What became clear is that companies with strong backlogs of customer business were rewarded and those with more economically sensitive customers underperformed. The best contributors were led by Vertiv Holdings Co., Advanced Energy Industries, Inc., and Curtiss- Wright Corporation. All three saw customer order growth adding to already strong backlogs in their respective fields of computing infrastructure, and aerospace/nuclear power. We continue to monitor their business closely for cracks in the foundation but remain confident that they are essential to customers and the prospects for growth are solid. Hardman Johnston Global Advisors LLC®, 300 Atlantic Street, Stamford, CT 06901 T203 324 4722 hardmanjohnston.com 4 Hardman Johnston Select Equity 2 0 2 6 F I R S T QU A R T E R R E P O R T Detractors were led by PayPal Holdings, Inc.. The company has not demonstrated that it can capitalize on what should be strong competitive advantages in the digital payments space, leading us to exit the position. Also detracting was IQVIA Holdings Inc.”
IQVIA Holdings Inc - March 2026
“Fears over potential disruption by AI weighed on our holding in IQVIA, which provides data services and research outsourcing to the healthcare sector. The market's concern is that that R&D across the healthcare sector will be disrupted by a new generation of powerful AI tools. After meeting with management and debating potential outcomes across the team, we reduced our position.”
IQVIA Holdings Inc - March 2026
“Detractors Individual holdings that detracted from performance during the quarter included Constellation Energy, IQVIA, Wayfair and Rocket Companies.”
IQVIA Holdings Inc - AddedBroyhill AMMarch 2026
“In the wake of this latest leg down, we significantly increased our investments in the sectors, bringing both IQVIA and Sotera Health into our top holdings.”
IQVIA Holdings Inc - June 2025
“• IQVIA Holdings (IQV) was a detractor during the quarter.”
IQVIA Holdings Inc - June 2025
“IQVIA Holdings (IQV) was a detractor during the quarter.”
IQVIA Holdings Inc - June 2025
“• IQVIA Holdings (IQV) was a detractor during the quarter.”
IQVIA Holdings Inc - December 2024
“Top detractors: • IQVIA Holdings was a detractor during the quar- ter.”
IQVIA Holdings Inc - December 2024
“• IQVIA Holdings was a detractor during the quar- ter. The U.S.-headquartered life sciences tools and services company’s stock price declined due to a reduced near-term outlook in its R&D solutions segment primarily related to a pro- gram cancellation and the delay of two large clinical trials that will resume in 2025. However, we believe that the headwinds in this part of the business should abate over the course of 2025. We are also encouraged that growth in the technology and analytics solutions segment is recovering as expected. We believe IQVIA stock is cheap at a mid-teens multiple of normal earnings power.”
IQVIA Holdings Inc
Fund coverage · 6 theses
- Artisan Partners Global Value FundSeptember 2026
IQVIA is seeing improving CRO demand, durable clinical-trials relevance despite AI concerns, and medium-term double-digit EPS growth potential.
Read the full thesis - Harris Associates U.S. Large Value StrategySeptember 2026
IQVIA combines improving demand, strong bookings, AI-enabled offerings, and a supportive long-term growth outlook.
Read the full thesis - Artisan U.S. Mid-Cap Value StrategyMarch 2026
IQVIA Holdings Inc combines scaled CRO operations with proprietary healthcare data assets that create a durable moat and strong cash flows, with cyclical and AI concerns offering attractive valuation.
Read the full thesis - Broyhill AMMarch 2026
IQVIA is a clinical research organization with sticky pharma demand, proprietary data, and valuation support despite AI concerns.
Read the full thesis - Vulcan Value PartnersJune 2025
IQVIA Holdings is the world's largest contract research organization, leveraging its extensive data and services to support drug development and commercialization while navigating current industry challenges.
Read the full thesis - Artisan Global Value StrategyJune 2025
IQVIA is a leading contract research organization that is poised for continued growth despite current industry headwinds, with a robust market share and attractive financial characteristics.
Read the full thesis
Read every full thesis on IQVIA Holdings Inc
Read all 6 theses in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→